NASDAQ · Biotechnology

Acelyrin, Inc. (SLRN) Stock

$2.27 +0.00% NASDAQ: SLRN Healthcare

Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies.

Valuation

MetricValue
Price$2.27
Market Cap$229.17M
P/E Ratio-0.91
P/B Ratio0.49
P/S Ratio0.00
EPS (TTM)$-2.50
52-Week High$7.25
52-Week Low$1.85
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-44.54%
ROA-50.54%
ROCE-68.08%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio18.10

Annual Financials (USD)

Metric2021202220232024
Revenue$0$0$0$0
Operating Profit$-42.0M$-69.0M$-422.0M$-316.0M
Net Profit$-42.0M$-250.0M$-382.0M$-248.0M
EPS$-2.05$-0.70$-5.43$-2.50
Op Margin————

Balance Sheet (USD)

Metric2021202220232024
Total Assets$102.0M$333.0M$743.0M$491.0M
Total Liabilities$144.0M$444.0M$86.0M$33.0M
Cash$102.0M$279.0M$218.0M$74.0M
Borrowings$0$0$1.0M$6.0M

Latest News

Horizon Bancorp Q2 Earnings, Revenue Rise MT Newswires · Jul 22, 2026 4 Leadership Habits That Build Sustainable Operational Standards FSR · Jul 22, 2026 Century Communities Q2 Adjusted Earnings, Revenue Fall MT Newswires · Jul 22, 2026 Filing of Leven Star Reef Technical Report GlobeNewswire · Jul 22, 2026 Home BancShares, Inc. Announces Increase in Quarterly Dividend GlobeNewswire · Jul 22, 2026

Cash Flow (USD)

Metric2021202220232024
Operating Cash Flow$-5.0M$-62.0M$-170.0M$-304.0M
Investing Cash Flow$-50.0M$-48.0M$-460.0M$154.0M
Financing Cash Flow$0$10.0M$-6.0M$-2.0M
Net Cash Flow$95.0M$165.0M$-49.0M$-144.0M
Free Cash Flow$-30.0M$-62.0M$-182.0M$-305.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.10
EV / EBITDA-0.65
FCF Yield-133.16%
Quick Ratio18.10
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CATBCatabasis Pharmaceuticals, Inc. $8.54 -6.97% -5.02 $234.86M 0.00%
CBLICytocom, Inc. $3.17 -7.31% -16.68 $226.39M 0.00%
CELUCelularity Inc. $0.75 +0.13% -0.20 $21.74M 0.00%
CRGXCARGO Therapeutics, Inc. Common Stock $4.47 +0.00% -1.59 $216.19M 0.00%
INXBInhibrx Biosciences, Inc. $15.86 +13.94% -10.29 $225.87M 0.00%

About Acelyrin, Inc.

Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies. The firm's most advanced experimental drug is izokibep, a potent small protein therapeutic specifically designed to block IL-17A. This compound is currently undergoing Phase 3 clinical evaluations for its use in treating Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis. Additionally, izokibep is being assessed in Phase 2 clinical trials for Axial Spondyloarthritis. Beyond izokibep, Acelyrin is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets the insulin-like growth factor 1 receptor. Lonigutamab is in Phase 1 clinical studies for individuals with thyroid eye disease. Furthermore, the company has SLRN-517, a fully human IgG1 monoclonal antibody aimed at c-KIT, which is in the preclinical stage of development for the treatment of chronic urticaria. Founded in 2020, Acelyrin's corporate headquarters are located in Agoura Hills, California.

Acelyrin, Inc. is headquartered in US.

Acelyrin, Inc. (SLRN) stock trades at $2.27 with a market capitalization of $229.17M. The stock is valued at a price-to-earnings (P/E) ratio of -0.91, price-to-book of 0.49, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.85 and $7.25, and currently trades 68.7% below its 52-week high.

On profitability, Acelyrin, Inc. generates a return on equity (ROE) of -44.54%, return on capital employed of -68.08%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.acelyrin.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides